Skip to main content
Log in

MAOI or ECT? Patient Preference and Joint Decision-Making in Treatment-Resistant Depression

  • Invited Commentary
  • Published:
Current Treatment Options in Psychiatry Aims and scope Submit manuscript

Abstract

The literature concurs that the classic monoamine oxidase inhibitors (MAOIs) and electroconvulsive therapy (ECT) are both vital treatment options for ‘treatment-resistant’ depression (TRD)—but ECT is commonly presented as an option and MAOIs are not. This is a significant deficit in current psychiatric practice and constitutes a violation of the joint decision-making paradigm. The patient cannot choose between options the physician does not offer, thereby precluding meaningful patient participation in treatment selection. We emphasize the favorable side-effect profile of MAOIs when contrasted with ECT and argue that MAOI treatment should generally be considered as either a prior or alternative step in the treatment protocol for TRD. This is in line with the recommendations in the Dutch stepped- and shared-care approach to TRD, as expressed in their Standard of Care for Depressive Disorders. We conclude this line of reasoning by stating that the physician is morally obliged to both improve his/her understanding of the merits of MAOI treatment, and to pass this knowledge on to his/her patients. Only then is informed choice possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Murgic L, Hébert PC, Sovic S, Pavlekovic G. Paternalism and autonomy: views of patients and providers in a transitional (post-communist) country. BMC Med Ethics. 2015;16(1):65. https://doi.org/10.1186/s12910-015-0059-z.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Fernández-Ballesteros R, Sánchez-Izquierdo M, Olmos R, Huici C, Ribera Casado JM, Cruz Jentoft A. Paternalism vs. autonomy: are they alternative types of formal care? Front Psychol. 2019;10:1460. https://doi.org/10.3389/fpsyg.2019.01460.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Berglund E, Lytsy P, Westerling R. The influence of locus of control on self-rated health in context of chronic disease: a structural equation modeling approach in a cross sectional study. BMC Public Health. 2014;14(1):492. https://doi.org/10.1186/1471-2458-14-492.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Zorgstandaard Depressieve stoornissen (2018). www.ggzstandaarden.nl. p 26, 52.

  5. O’Leary CJ, Nasser A, Myland M, Waples S, Ansell D. Audit of irreversible monoamine oxidase inhibitors (MAOI) prescription for depression in current Clinical practice within the Health improvement Network (THIN) UK primary care database. Value Health. 2015;18(3):A125–6. https://doi.org/10.1016/j.jval.2015.03.732.

    Article  Google Scholar 

  6. Lyndon B. Withdrawal of useful drugs from the market. Aust Prescr. 2003;26:99–102. https://doi.org/10.18773/austprescr.2003.035.

    Article  Google Scholar 

  7. Suchting R, Tirumalaraju V, Gareeb R, Bockmann T, de Dios C, Aickareth J, et al. Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: a systematic review and network meta-analysis. J Affect Disord. 2021;282:1153–60. https://doi.org/10.1016/j.jad.2021.01.021.

    Article  CAS  PubMed  Google Scholar 

  8. Ricken R, Ulrich S, Schlattmann P, Adli M. Tranylcypromine in mind (part II): review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol. 2017;27(8):714–31. https://doi.org/10.1016/j.euroneuro.2017.04.003.

    Article  CAS  PubMed  Google Scholar 

  9. Abbott CC, Lemke NT, Gopal S, Thoma RJ, Bustillo J, Calhoun VD, et al. Electroconvulsive therapy response in major depressive disorder: a pilot functional network connectivity resting state FMRI investigation. Front Psychiatry. 2013;4:10. https://doi.org/10.3389/fpsyt.2013.00010.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Porter RJ, Baune BT, Morris G, Hamilton A, Bassett D, Boyce P, et al. Cognitive side-effects of electroconvulsive therapy: what are they, how to monitor them and what to tell patients. BJPsych Open. 2020;6(3):e40-e. https://doi.org/10.1192/bjo.2020.17.

  11. Wells K, Hancock N, Honey A. The experience of living after ECT: a qualitative meta-synthesis. J Ment Health. 2021;30(4):526–40. https://doi.org/10.1080/09638237.2020.1739244.

    Article  CAS  PubMed  Google Scholar 

  12. Gillman PK, Feinberg SS, Fochtmann LJ. Revitalizing monoamine oxidase inhibitors: a call for action. CNS Spectr. 2020;25(4):452–4. https://doi.org/10.1017/S1092852919001196.

    Article  PubMed  Google Scholar 

  13. Gillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol. 2011;31(1):66–74. https://doi.org/10.1097/JCP.0b013e31820469ea.

    Article  CAS  PubMed  Google Scholar 

  14. Van den Eynde V, Gillman PK, Blackwell BB. The prescriber’s guide to the MAOI diet - Thinking through tyramine troubles. Psychopharmacol Bull. 2022;52(2):73–116.

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Dr. Natalie Rasgon for reviewing their manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vincent Van den Eynde LL.M..

Ethics declarations

Conflict of interest

VVdE is an external research consultant for and receives or has received consulting fees from PsychoTropical Research, NeuraWell Therapeutics, Aristo Pharma GmbH; he has stock options in NeuraWell Therapeutics.

PKG has equity interests in and is on the advisory board of NeuraWell Therapeutics, the company that has the patent for a modified form of tranylcypromine.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Van den Eynde, V., Gillman, P.K. MAOI or ECT? Patient Preference and Joint Decision-Making in Treatment-Resistant Depression. Curr Treat Options Psych 9, 419–422 (2022). https://doi.org/10.1007/s40501-022-00277-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40501-022-00277-z

Navigation